Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Overview of the global human respiratory syncytial virus drugs market

The global human respiratory syncytial virus (RSV) drugs market is anticipated to grow at a steady rate and post a CAGR of more than 4% during the forecast period. The increasing usage of novel diagnostic tools will drive the growth prospects for the global human respiratory syncytial virus drugs market until the end of 2020. Novel diagnostic tools are used to detect, screen, and evaluate individuals with respiratory syncytial virus (RSV). Some of the novel diagnostic methods include rapid diagnostic assays, RT-PCR assays, and serological tests. Also, the vendors and researchers are increasingly focusing on the development of novel diagnostic tests due to the rising demand for accurate diagnosis. For instance, Quidel offers the Lyra RSV + hMPV assay for the qualitative detection and identification of RSV. Such diagnostic tools deliver results equivalent to central laboratory standards within 70 minutes and are more effective and accurate. Other such products include Idylla Respiratory IFV-RSV Panel for the detection of various strains of RSV and influenza virus.

The active participation of emerging economies toward research and development will drive the growth prospects for the market during the forecast period. The increasing R&D activities in emerging economies for RSV infection and its causes will fuel the development of novel drugs. One of the major factors responsible for the market’s growth is the rising amount of patented therapies for RSV treatment that result in substantial R&D activities from various big pharma companies and research institutes. For instance, in June 2016, the Lancet Respiratory Medicine reported that RSV was the most commonly detected pathogen linked with pneumonia among children in South Africa. Such new findings will increase the scope of anti-RSV drugs in new applications, such as pneumonia.

Competitive landscape and key vendors

The global human respiratory syncytial virus drugs market is highly dominated by few major vendors, who sell Synagis in their respective markets. Also, other vendors offer bronchodilators as off-label drugs, which does not substantially impact the market’s growth. The emerging vendors are also focusing on undertaking R&D activities to help develop RSV vaccines for individuals of ages more than 60.  

Key vendors in this market are -

• AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical

Other prominent vendors in the market include Ablynx, ADMA Biologics, Alnylam Pharmaceuticals, Ark Biosciences, Aviragen Therapeutics, Bavarian Nordic, Boehringer Ingelheim, Gilead Sciences, ImmunoVaccine Technologies, Johnson & Johnson, Kyowa Hakko Kirin, Medivir, Mucosis, Mymetics, Novavax, Regeneron Pharmaceuticals, ReViral, and Vaxart.

Segmentation by category of drug and analysis of the human respiratory syncytial virus drugs market

• Approved drugs
• Off-label drugs

The approved drugs segment accounted for the maximum market share during 2015 and will continue to dominate the market for the next few years. The market is expected to witness the launch of several biologics, such as monoclonal antibodies, vaccines, and RNAi therapeutics over the forecast period, which will, in turn, drive this market segment’s growth.

Segmentation by geography and analysis of the human respiratory syncytial virus drugs market

• Europe
• US
• ROW

In terms of geography, ROW accounted for the maximum market share during 2015 and will continue to dominate the market for the next few years. One of the major factors responsible for the market’s growth in the region is the growing incidence of RSV infections in ROW, including the BRIC nations.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global human respiratory syncytial virus drugs market?
• What are the key market trends impacting the growth of the global human respiratory syncytial virus drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global human respiratory syncytial virus drugs market?
• What are the market opportunities and threats faced by the vendors in the global human respiratory syncytial virus drugs market?
• What are the trending factors influencing the market shares of Europe, the US, and ROW?
• What are the key outcomes of the five forces analysis of the global human respiratory syncytial virus drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Respiratory Drugs Market 2016-2020
• Global Respiratory Protection Equipment Market 2016-2020